Talk:Atropa belladonna/Archives/2020/February

Bulgarian Cure
maybe a new section should be added concerning the contribution of belladdonna in the parkinson treatment: — Preceding unsigned comment added by CristianChirita (talk • contribs)

A. belladonna ssp. caucasica : Caucasian Belladonna
This section below the line is removed for discussion per WP:BRD because it has dubious value and comes from a vague source onerous to digest, WP:NOTTEXTBOOK, #6. The significance of the topic as a subspecies isn't clear, as the subspecies is obscure without cross-referencing, and its source is limited to one Russian reference. Also, the writing, formatting, and in-text use of background are carelessly prepared, an edit which I tried to repair here. I really don't see the value of this addition of a rare subspecies; WP:NOTEVERYTHING applies. --Zefr (talk) 16:00, 17 April 2018 (UTC)

________________

Russian botanist Georgij Karlowic Kreyer ( 1887-1942 ) published the species name Atropa caucasica in 1925 : publication : Result. schestiletn. nabl. 48.

Bobrov and Schischkin, in their monumental Flora of the Soviet Union of 1955, still list Atropa caucasica as a distinct species, but this has since been demoted to the rank of a subspecies : ''Atropa belladonna ssp. caucasica'' (Kreyer) Avet.

The subspecies name ''Atropa belladonna ssp. caucasica'' was published in Yerevan by noted Armenian botanist and mycologist Vandika Ervandovna Avetisyan ( born 1928 ) in Biologicheskii Zhurnal Armenii ( Armenian Journal of Biology ) 34(9): 908 in 1981.

Plants of the Caucasian subspecies differ from those of common Belladonna in the following respects : a) the stem is usually completely glabrous ( = hairless ) along its entire length ( including inflorescence ) and is generally glaucous(though occasionally diffusely glandular-pubescent below the inflorescence); b)  the leaf veins are likewise usually glabrous; and c)  the flowers are, on average, larger and, according to Kreyer, broader in the throat and lighter in colour, brownish or violet-red in their upper parts and having a yellow pattern in their lower parts.

A. belladonna ssp. caucasica has a distribution encompassing Circassia and adjoining regions of western-central Ciscaucasia and ( in Transcaucasia ) Abkhazia, Georgia, Armenia and Azerbaijan. Also the Talysh Mountains (shared by Azerbaijan and northwestern Iran), Kurdistan, Turkey and the Balkans.

Caucasian Belladonna grows in mountain forests of the lower to middle zones, mainly among Beeches. It favours cool, north-facing or northeast-facing slopes, clearings, moist glades, windbreaks and forest margins, and grows in friable, humus-rich soils. Flowering occurs from the second half of May to the first half of September and fruiting from the second half of June to the first half of October.

This subspecies was first described from plants raised from seed collected in Sukhumi and Tbilisi. The type specimen may have been lost.

"In spite of the absence ( or nonappearance ) of constant distinctive features, the Caucasian race of belladonna reveals a high constancy of features very rarely observed in European and Crimean plants...even physiological differences have been observed, as, for example, a 3-5 times as long seed germination period for Caucasian belladonna. A thorough comparative study of plants of both races under natural conditions and a comparative study of their physiological and chemical properties should be continued."

Legal status
This section is misleading and is not cited. 4Cancer (talk) 01:48, 28 August 2019 (UTC)

Correction: Cited using Erowid...which is pretty much like citing the Dark Web's Silk Road...except from the wayback machine. Does Wikipedia really support this? Because I don't see anyone doing anything... You're following my page, you know I'm trying to get attention towards this...and since I'm a newbie, I really don't feel I have auth to do anything. 4Cancer (talk) 02:29, 28 August 2019 (UTC)
 * Made this edit using the Drugs.com review and correct FDA source for atropine in cold medicine products. Not aware of further FDA sources, since there are no approved drugs, and the cold medicines as OTC supplements cannot claim efficacy or guarantee safety at doses higher than 0.2 mg. --Zefr (talk) 04:43, 28 August 2019 (UTC)